NUC in Preventing HBV Reactivation in HCV/HBV Co-infected Patients Receiving DAA for CHC

NCT ID: NCT04405011

Last Updated: 2020-07-02

Basic Information

• Recruitment Status: UNKNOWN
• Clinical Phase: NA
• Total Enrollment: 60 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2018-08-01
• Study Completion Date: 2020-12-28

Brief Summary

HBV reactivation is common in HCV/HBV coinfected patients receiving DAA therapy for chronic hepatitis C. How to prevent HBV reactivation remains unclear. In this trial, we aim to investigate whether prophylactic nucleos(t)ide analogue (NUC) at the start of DAA could prevent HBV reactivation or not. And whether prolonged NUC prophylaxis (24 weeks) would be better than 12-week prophylaxis. This will be a three-arm, open-label, randomized, active controlled, study. Totally, 60 HBV/HCV co-infected treatment-naïve or treatment-experienced patients without decompensated liver cirrhosis will be included in this study. Group 1 patients (n=20) will receive 12-week ETV from the start of DAA therapy. Group 2 patients (n=20) will receive 24-week ETV from the start of DAA till 12 weeks after end of DAA. Group 3 patients (n=20) will not receive ETV during the period of DAA and will serve as controls. The rate of HBV reactivation and clinical reactivation will be compared among 3 groups of patients. Expected outcomes: The rate of HBV reactivation and clinical reactivation will be lower in the ETV prophylaxis group, and will be the lowest in the group receiving 24-week ETV prophylaxis.

Detailed Description

We will determine the incidence of virologic and clinical reactivation of HBV during DAA treatment for CHC, in two prophylactic groups versus control group. We will also examine whether extending the duration of prophylactic NUC would be more beneficial than the 3-month prophylaxis regimen.

Patients with the following criteria will be enrolled: age ≥20 years; anti-HCV positive and HCV RNA >1000 IU/ml; any HCV genotype; all received 12 weeks of DAA treatment; treatment naïve or experienced of pegylated interferon/ribavirin; concurrent HBV infection which is defined by positive HBsAg for at least 6 months. Patients with the following criteria will be excluded: history of treatment regimen that included any kind of direct antiviral agents; presence of other etiology of chronic hepatitis including HIV, autoimmune hepatitis, NASH, etc; uncontrolled diabetes mellitus (Hba1c >8.5); current evidence or suspicion of malignancy; severe cardiovascular or other severe comorbid diseases; autoimmune disorders; presence of liver cirrhosis clinically or pathologically; any one of following hematology or biochemical or clinical abnormalities: AST/ALT >10x ULN, Albumin <3.5g/dL, Bilirubin >2.5mg/dL, eGFR <30 ml/min/1.73m2, prothrombin time prolongation >4 sec or INR >1.7, platelet count <100 x 103 uL, and history or presence of ascites or hepatic encephalopathy; child-bearing age women without the willing to contraceptive control; and pregnant women or lactating women.

Briefly, 60 HCV/HBV coinfected patients will be enrolled and randomized to receive 12-week DAA regimen for reimbursed for the the treatment of patients with CHC in Taiwan.

Entecavir (0.5mg; ETV) 1 # daily will be used in the prophylactic group. Group 1 patients (n=20) will receive 12-week ETV from the start of DAA therapy. Group 2 patients (n=20) will receive 24-week ETV from the start of DAA till 12 weeks after end of DAA. Group 3 patients (n=20) will not receive ETV during the period of DAA and serve as controls. The rate of HBV reactivation and clinical reactivation will be compared among 3 groups of patients.

The primary endpoint will be the incidence of virologic and clinical reactivation of HBV during DAA treatment for CHC. Secondary objectives include the rate of HBV virologic and clinical reactivation between 12-week versus 24-week entecavir (ETV) prophylaxis during and after DAA treatment; the profiles of serum HBV DNA/qHBsAg during and after DAA treatment; and sustained virological response at post-DAA treatment 12 weeks (SVR12).

The data will be expressed as percentages for category variables and as mean +- standard deviation for continuous variables. Category variables will be evaluated by Chi-square test or Fisher exact test. Student's t test or Mann-Whitney U test will be applied for comparison of the continuous variables. Multivariate analysis will be used to identify factors that are associated with HBV reactivation. A p value less than 0.05 is considered to be significant.

Conditions

HBV/HCV Co-infection

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: FACTORIAL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

Entecavir 0.5mg daily for 24 weeks

Entecavir will be delivered for 24-week and will be the experimental arm

Group Type: EXPERIMENTAL

24-week Entecavir

Intervention Type: DRUG

Entecavir 0.5mg for 24 weeks will be delivered

Entecavir 0.5mg daily for 12 weeks

12-week entecavir will be served as active comparator

Group Type: ACTIVE_COMPARATOR

12-week Entecavir

Intervention Type: DRUG

Entecavir for 12 weeks will be delivered and serve as the active comparator arm

Control

Control group does not receive prophylactic ETV

Group Type: NO_INTERVENTION

No interventions assigned to this group

Interventions

24-week Entecavir

Entecavir 0.5mg for 24 weeks will be delivered

Intervention Type: DRUG

12-week Entecavir

Entecavir for 12 weeks will be delivered and serve as the active comparator arm

Intervention Type: DRUG

Other Intervention Names

Prophylaxis arm 1; Prophylaxis arm 2

Eligibility Criteria

Inclusion Criteria

1. Age ≥20 years;

2. Anti-HCV positive and HCV RNA >1000 IU/ml;

3. Any HCV genotype; all received 12 weeks of DAA treatment.

4. Treatment naïve or experienced of pegylated interferon/ribavirin;

5. Concurrent HBV infection which is defined by positive HBsAg for at least 6 months.

Exclusion Criteria

1. History of treatment regimen that included any kind of direct antiviral agents;

2. Presence of other etiology of chronic hepatitis including HIV, autoimmune hepatitis, NASH, etc;

3. Uncontrolled diabetes mellitus (Hba1c >8.5);

4. Current evidence or suspicion of malignancy;

5. Severe cardiovascular or other severe comorbid diseases;

6. Autoimmune disorders;

7. Presence of liver cirrhosis clinically or pathologically;

8. Any one of following hematology or biochemical or clinical abnormalities:

AST/ALT >10x ULN, Albumin <3.5g/dL, Bilirubin >2.5mg/dL, eGFR <30 ml/min/1.73m2, prothrombin time prolongation >4 sec or INR >1.7, platelet count <100 x 103 uL, and history or presence of ascites or hepatic encephalopathy.

9. Child-bearing age women without the willing to contraceptive control; pregnant women or lactating women.

• Minimum Eligible Age: 20 Years
• Maximum Eligible Age: 70 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

National Taiwan University Hospital

OTHER

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Chun-Jen Liu, MDPHD

Role: PRINCIPAL_INVESTIGATOR

Department of Internal Medicine, NTUH

Locations

National Taiwan University Hospital

Taipei, , Taiwan

Site Status: RECRUITING

TC Chen

Taipei, , Taiwan

Site Status: RECRUITING

Countries

Taiwan

Central Contacts

Chun-Jen Liu

Role: CONTACT

cjliu@ntu.edu.tw

0972651071

Ting-Chih Chen

Role: CONTACT

tingchih@g.ntu.edu.tw

0920228525

Facility Contacts

Chun-Jen Liu, MDPHD

Role: primary

cjliu@ntu.edu.tw

0972651071

References

Cheng PN, Liu CJ, Chen CY, Tseng KC, Lo CC, Peng CY, Lin CL, Chiu HC, Chiu YC, Chen PJ. Entecavir Prevents HBV Reactivation During Direct Acting Antivirals for HCV/HBV Dual Infection: A Randomized Trial. Clin Gastroenterol Hepatol. 2022 Dec;20(12):2800-2808. doi: 10.1016/j.cgh.2021.11.032. Epub 2021 Dec 2.

Reference Type: DERIVED

PMID: 34864158 (View on PubMed)

Other Identifiers

201807069MINB

Identifier Type: -

Identifier Source: org_study_id